High Speed Analysis of Indometacin in accordance with chapter 621 in USP 39

Significance of the Topic

In modern pharmaceutical analysis, rapid and reliable quantification of active ingredients is essential for maintaining product quality and regulatory compliance. High-performance liquid chromatography (HPLC) remains a cornerstone technique, and methods that meet United States Pharmacopoeia (USP) requirements while reducing run time can greatly improve laboratory throughput and cost efficiency.

Objectives and Study Overview

This work demonstrates an accelerated isocratic HPLC procedure for the quantification of Indometacin in accordance with USP Chapter <621>. The goal is to apply the permissible adjustments defined by USP to shorten analysis time without compromising resolution, system suitability, or regulatory compliance.

Methodology and Instrumentation

The method development follows USP 621 guidelines, allowing modification of column length (–25 % to +50 %), particle size (±50 %), inner diameter, flow rate, temperature (±10 °C), and injection volume within acceptable ranges.

• Original method: 250 mm × 4.6 mm, 5 µm column; 1.5 mL/min; 10 µL injection; 30 °C.
• Fast method: 150 mm × 3.0 mm, 3 µm column; 1.2 mL/min; 5 µL injection; 30 °C.

The system comprised a Shimadzu LC-2040C 3D pump, Shim-pack GIST C18-AQ columns, mobile phase of 0.1 % formic acid and acetonitrile (55/45, v/v), and PDA detection from 190–800 nm.

Main Results and Discussion

The accelerated protocol reduced retention times from 25.5 to 9.5 min for Indometacin and proportionally for related impurities, representing a 63 % decrease in runtime. System suitability tests confirmed resolution ≥2.0 and tailing factors ≤1.2 for all peaks, meeting and exceeding USP criteria while cutting solvent usage by approximately 20 %.

Benefits and Practical Applications

This optimized HPLC procedure enables higher daily sample throughput and lower operational costs due to reduced analysis time and solvent consumption. It can be readily adopted in quality control laboratories to streamline routine testing of nonsteroidal anti-inflammatory drug formulations.

Future Trends and Opportunities

Continued advances in ultrahigh-performance LC, sub-2 µm particle columns, and automated method scouting will further accelerate analyses. Integration with digital and AI-driven workflows may enable real-time method adjustments and enhanced data quality assurance.

Conclusion

By leveraging USP 621 flexibility, the fast HPLC method for Indometacin delivers regulatory-compliant performance with substantially reduced analysis time and solvent use, supporting efficient pharmaceutical quality control.